CD209

Across TCGA pan-cancer cohorts, CD209 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated CD209 data layer compared with 17 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher CD209 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CD209 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

STAD, UCEC, and ESCA are the cancer types where CD209 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	IV	0.001	0.544	<.001	36	view →
UCEC	DFS	Median	All	0.963	0.617	.008	30	view →
ESCA	OS	Median	II,III,IV	0.164	0.687	.002	24	view →
LUSC	OS	Median	II,III,IV	0.290	0.635	.016	18	view →
KIRC	OS	Median	All	0.141	0.655	.026	12	view →
PRAD	DFS	Median	All	0.157	0.888	<.001	12	view →
BLCA	DFS	Median	III,IV	0.823	0.267	.031	7	view →
UCS	DFS	Median	All	0.136	0.523	.034	6	view →
CESC	OS	Median	II,III,IV	0.203	0.759	.021	6	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

CD209–STAD (OS)

Open the STAD breakdown →